NuVasive, Inc. (NASDAQ: NUVA) Stock Competitors & Peer Comparison
See NUVA's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for NUVA and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NUVA | $39.75 | -2.24% | 2.1B | 75.00 | $0.53 | N/A |
| ABT | $111.27 | +0.32% | 192.6B | 21.36 | $5.21 | +2.23% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| SYK | $341.09 | -1.76% | 130.8B | 25.47 | $13.39 | +1.02% |
| MDT | $90.58 | -0.20% | 116B | 16.38 | $5.53 | +3.14% |
| BSX | $51.69 | +0.53% | 76.9B | 16.68 | $3.10 | N/A |
| EW | $92.56 | -0.53% | 53.3B | 34.29 | $2.70 | N/A |
| DXCM | $91.48 | +0.75% | 34.5B | 39.26 | $2.33 | N/A |
| RMD | $226.74 | +0.33% | 32.9B | 21.06 | $10.77 | +1.05% |
| PHG | $27.38 | +2.16% | 26.8B | 15.64 | $1.75 | +3.62% |
Stock Comparison
Abbott Laboratories (NYSE: ABT)
NUVA vs ABT Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, ABT has a market cap of 192.6B. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while ABT trades at $111.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas ABT's P/E ratio is 21.36. In terms of profitability, NUVA's ROE is +0.05%, compared to ABT's ROE of +0.11%. Regarding short-term risk, NUVA is more volatile compared to ABT. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check ABT's competition here
Boston Scientific Corporation (NYSE: BSX-PA)
NUVA vs BSX-PA Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, NUVA's ROE is +0.05%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, NUVA is more volatile compared to BSX-PA. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check BSX-PA's competition here
Stryker Corporation (NYSE: SYK)
NUVA vs SYK Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, SYK has a market cap of 130.8B. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while SYK trades at $341.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas SYK's P/E ratio is 25.47. In terms of profitability, NUVA's ROE is +0.05%, compared to SYK's ROE of +0.16%. Regarding short-term risk, NUVA is more volatile compared to SYK. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check SYK's competition here
Medtronic plc (NYSE: MDT)
NUVA vs MDT Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, MDT has a market cap of 116B. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while MDT trades at $90.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas MDT's P/E ratio is 16.38. In terms of profitability, NUVA's ROE is +0.05%, compared to MDT's ROE of +0.10%. Regarding short-term risk, NUVA is more volatile compared to MDT. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check MDT's competition here
Boston Scientific Corporation (NYSE: BSX)
NUVA vs BSX Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, BSX has a market cap of 76.9B. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while BSX trades at $51.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas BSX's P/E ratio is 16.68. In terms of profitability, NUVA's ROE is +0.05%, compared to BSX's ROE of +0.15%. Regarding short-term risk, NUVA is more volatile compared to BSX. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check BSX's competition here
Edwards Lifesciences Corporation (NYSE: EW)
NUVA vs EW Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, EW has a market cap of 53.3B. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while EW trades at $92.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas EW's P/E ratio is 34.29. In terms of profitability, NUVA's ROE is +0.05%, compared to EW's ROE of +0.10%. Regarding short-term risk, NUVA is more volatile compared to EW. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check EW's competition here
DexCom, Inc. (NASDAQ: DXCM)
NUVA vs DXCM Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, DXCM has a market cap of 34.5B. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while DXCM trades at $91.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas DXCM's P/E ratio is 39.26. In terms of profitability, NUVA's ROE is +0.05%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, NUVA is more volatile compared to DXCM. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check DXCM's competition here
ResMed Inc. (NYSE: RMD)
NUVA vs RMD Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, RMD has a market cap of 32.9B. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while RMD trades at $226.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas RMD's P/E ratio is 21.06. In terms of profitability, NUVA's ROE is +0.05%, compared to RMD's ROE of +0.24%. Regarding short-term risk, NUVA is more volatile compared to RMD. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check RMD's competition here
Koninklijke Philips N.V. (NYSE: PHG)
NUVA vs PHG Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, PHG has a market cap of 26.8B. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while PHG trades at $27.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas PHG's P/E ratio is 15.64. In terms of profitability, NUVA's ROE is +0.05%, compared to PHG's ROE of +0.10%. Regarding short-term risk, NUVA is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check PHG's competition here
Zimmer Biomet Holdings, Inc. (NYSE: ZBH)
NUVA vs ZBH Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, ZBH has a market cap of 19.3B. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while ZBH trades at $99.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas ZBH's P/E ratio is 11.74. In terms of profitability, NUVA's ROE is +0.05%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, NUVA is more volatile compared to ZBH. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check ZBH's competition here
Abiomed, Inc. (NASDAQ: ABMD)
NUVA vs ABMD Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas ABMD's P/E ratio is 65.36. In terms of profitability, NUVA's ROE is +0.05%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, NUVA is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check ABMD's competition here
Penumbra, Inc. (NYSE: PEN)
NUVA vs PEN Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, PEN has a market cap of 12.9B. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while PEN trades at $326.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas PEN's P/E ratio is 85.36. In terms of profitability, NUVA's ROE is +0.05%, compared to PEN's ROE of +0.11%. Regarding short-term risk, NUVA is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check PEN's competition here
Smith & Nephew plc (NYSE: SNN)
NUVA vs SNN Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, SNN has a market cap of 12.7B. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while SNN trades at $30.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas SNN's P/E ratio is 14.17. In terms of profitability, NUVA's ROE is +0.05%, compared to SNN's ROE of +0.12%. Regarding short-term risk, NUVA is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check SNN's competition here
Align Technology, Inc. (NASDAQ: ALGN)
NUVA vs ALGN Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, ALGN has a market cap of 12.6B. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while ALGN trades at $176.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas ALGN's P/E ratio is 16.06. In terms of profitability, NUVA's ROE is +0.05%, compared to ALGN's ROE of +0.14%. Regarding short-term risk, NUVA is more volatile compared to ALGN. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check ALGN's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
NUVA vs SWAV Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas SWAV's P/E ratio is 78.76. In terms of profitability, NUVA's ROE is +0.05%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, NUVA is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check SWAV's competition here
Globus Medical, Inc. (NYSE: GMED)
NUVA vs GMED Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, GMED has a market cap of 11.6B. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while GMED trades at $85.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas GMED's P/E ratio is 19.36. In terms of profitability, NUVA's ROE is +0.05%, compared to GMED's ROE of +0.12%. Regarding short-term risk, NUVA is more volatile compared to GMED. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check GMED's competition here
Glaukos Corporation (NYSE: GKOS)
NUVA vs GKOS Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, GKOS has a market cap of 11.2B. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while GKOS trades at $189.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas GKOS's P/E ratio is -220.30. In terms of profitability, NUVA's ROE is +0.05%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, NUVA is more volatile compared to GKOS. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check GKOS's competition here
Insulet Corp. (NASDAQ: PODD)
NUVA vs PODD Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, PODD has a market cap of 10.1B. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while PODD trades at $146.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas PODD's P/E ratio is 24.95. In terms of profitability, NUVA's ROE is +0.05%, compared to PODD's ROE of +0.27%. Regarding short-term risk, NUVA is more volatile compared to PODD. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check PODD's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO)
NUVA vs BIO Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, BIO has a market cap of 9.7B. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while BIO trades at $361.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas BIO's P/E ratio is 38.93. In terms of profitability, NUVA's ROE is +0.05%, compared to BIO's ROE of +0.03%. Regarding short-term risk, NUVA is more volatile compared to BIO. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check BIO's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO-B)
NUVA vs BIO-B Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, BIO-B has a market cap of 9.5B. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while BIO-B trades at $348.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas BIO-B's P/E ratio is 103.33. In terms of profitability, NUVA's ROE is +0.05%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, NUVA is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check BIO-B's competition here
Masimo Corporation (NASDAQ: MASI)
NUVA vs MASI Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas MASI's P/E ratio is 44.43. In terms of profitability, NUVA's ROE is +0.05%, compared to MASI's ROE of +0.09%. Regarding short-term risk, NUVA is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check MASI's competition here
Bruker Corporation (NASDAQ: BRKR)
NUVA vs BRKR Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, BRKR has a market cap of 8.8B. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while BRKR trades at $57.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas BRKR's P/E ratio is 29.11. In terms of profitability, NUVA's ROE is +0.05%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, NUVA is less volatile compared to BRKR. This indicates lower risk in terms of short-term price fluctuations for NUVA.Check BRKR's competition here
Inari Medical, Inc. (NASDAQ: NARI)
NUVA vs NARI Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas NARI's P/E ratio is -59.24. In terms of profitability, NUVA's ROE is +0.05%, compared to NARI's ROE of -0.00%. Regarding short-term risk, NUVA is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check NARI's competition here
LivaNova PLC (NASDAQ: LIVN)
NUVA vs LIVN Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, LIVN has a market cap of 4.4B. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while LIVN trades at $82.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas LIVN's P/E ratio is 19.19. In terms of profitability, NUVA's ROE is +0.05%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, NUVA is more volatile compared to LIVN. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check LIVN's competition here
Integer Holdings Corporation (NYSE: ITGR)
NUVA vs ITGR Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, ITGR has a market cap of 4.2B. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while ITGR trades at $125.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas ITGR's P/E ratio is 19.69. In terms of profitability, NUVA's ROE is +0.05%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, NUVA is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check ITGR's competition here
Haemonetics Corporation (NYSE: HAE)
NUVA vs HAE Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, HAE has a market cap of 4.1B. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while HAE trades at $90.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas HAE's P/E ratio is 18.06. In terms of profitability, NUVA's ROE is +0.05%, compared to HAE's ROE of +0.11%. Regarding short-term risk, NUVA is more volatile compared to HAE. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check HAE's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
NUVA vs IRTC Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, IRTC has a market cap of 4B. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while IRTC trades at $123.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas IRTC's P/E ratio is -192.44. In terms of profitability, NUVA's ROE is +0.05%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, NUVA is more volatile compared to IRTC. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check IRTC's competition here
Axonics, Inc. (NASDAQ: AXNX)
NUVA vs AXNX Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas AXNX's P/E ratio is -709.80. In terms of profitability, NUVA's ROE is +0.05%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, NUVA is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check AXNX's competition here
TransMedics Group, Inc. (NASDAQ: TMDX)
NUVA vs TMDX Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, TMDX has a market cap of 3.1B. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while TMDX trades at $89.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas TMDX's P/E ratio is 45.50. In terms of profitability, NUVA's ROE is +0.05%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, NUVA is more volatile compared to TMDX. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check TMDX's competition here
AxoGen, Inc. (NASDAQ: AXGN)
NUVA vs AXGN Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, AXGN has a market cap of 2.6B. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while AXGN trades at $48.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas AXGN's P/E ratio is 126.45. In terms of profitability, NUVA's ROE is +0.05%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, NUVA is less volatile compared to AXGN. This indicates lower risk in terms of short-term price fluctuations for NUVA.Check AXGN's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
NUVA vs UFPT Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, UFPT has a market cap of 2.5B. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while UFPT trades at $319.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas UFPT's P/E ratio is 32.67. In terms of profitability, NUVA's ROE is +0.05%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, NUVA is more volatile compared to UFPT. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check UFPT's competition here
Butterfly Network, Inc. (NYSE: BFLY)
NUVA vs BFLY Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, BFLY has a market cap of 2.4B. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while BFLY trades at $8.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas BFLY's P/E ratio is -36.79. In terms of profitability, NUVA's ROE is +0.05%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, NUVA is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for NUVA.Check BFLY's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
NUVA vs ESTA Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, ESTA has a market cap of 2.2B. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while ESTA trades at $75.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas ESTA's P/E ratio is -59.99. In terms of profitability, NUVA's ROE is +0.05%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, NUVA is less volatile compared to ESTA. This indicates lower risk in terms of short-term price fluctuations for NUVA.Check ESTA's competition here
Novocure Ltd (NASDAQ: NVCR)
NUVA vs NVCR Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, NVCR has a market cap of 2B. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while NVCR trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas NVCR's P/E ratio is -11.36. In terms of profitability, NUVA's ROE is +0.05%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, NUVA is more volatile compared to NVCR. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check NVCR's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
NUVA vs INSP Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, INSP has a market cap of 1.7B. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while INSP trades at $58.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas INSP's P/E ratio is 25.62. In terms of profitability, NUVA's ROE is +0.05%, compared to INSP's ROE of +0.18%. Regarding short-term risk, NUVA is more volatile compared to INSP. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check INSP's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
NUVA vs TNDM Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, TNDM has a market cap of 1.6B. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while TNDM trades at $23.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas TNDM's P/E ratio is -21.03. In terms of profitability, NUVA's ROE is +0.05%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, NUVA is more volatile compared to TNDM. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check TNDM's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
NUVA vs ATEC Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, ATEC has a market cap of 1.5B. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while ATEC trades at $9.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas ATEC's P/E ratio is -162.50. In terms of profitability, NUVA's ROE is +0.05%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, NUVA is more volatile compared to ATEC. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check ATEC's competition here
CONMED Corporation (NYSE: CNMD)
NUVA vs CNMD Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, CNMD has a market cap of 1.5B. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while CNMD trades at $49.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas CNMD's P/E ratio is 10.94. In terms of profitability, NUVA's ROE is +0.05%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, NUVA is more volatile compared to CNMD. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check CNMD's competition here
Enovis Corporation (NYSE: ENOV)
NUVA vs ENOV Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, ENOV has a market cap of 1.5B. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while ENOV trades at $25.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas ENOV's P/E ratio is 7.36. In terms of profitability, NUVA's ROE is +0.05%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, NUVA is less volatile compared to ENOV. This indicates lower risk in terms of short-term price fluctuations for NUVA.Check ENOV's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
NUVA vs IART Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, IART has a market cap of 1.4B. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while IART trades at $18.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas IART's P/E ratio is 7.73. In terms of profitability, NUVA's ROE is +0.05%, compared to IART's ROE of -0.01%. Regarding short-term risk, NUVA is less volatile compared to IART. This indicates lower risk in terms of short-term price fluctuations for NUVA.Check IART's competition here
Artivion, Inc. (NYSE: AORT)
NUVA vs AORT Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, AORT has a market cap of 1.4B. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while AORT trades at $28.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas AORT's P/E ratio is 47.38. In terms of profitability, NUVA's ROE is +0.05%, compared to AORT's ROE of -0.01%. Regarding short-term risk, NUVA is more volatile compared to AORT. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check AORT's competition here
Heska Corporation (NASDAQ: HSKA)
NUVA vs HSKA Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas HSKA's P/E ratio is -62.49. In terms of profitability, NUVA's ROE is +0.05%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, NUVA is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check HSKA's competition here
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
NUVA vs PRCT Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, PRCT has a market cap of 1.2B. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while PRCT trades at $21.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas PRCT's P/E ratio is -11.31. In terms of profitability, NUVA's ROE is +0.05%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, NUVA is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for NUVA.Check PRCT's competition here
Avanos Medical, Inc. (NYSE: AVNS)
NUVA vs AVNS Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while AVNS trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas AVNS's P/E ratio is 27.77. In terms of profitability, NUVA's ROE is +0.05%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, NUVA is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check AVNS's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
NUVA vs LMRI Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, LMRI has a market cap of 1.1B. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while LMRI trades at $12.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas LMRI's P/E ratio is -22.82. In terms of profitability, NUVA's ROE is +0.05%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, NUVA is less volatile compared to LMRI. This indicates lower risk in terms of short-term price fluctuations for NUVA.Check LMRI's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
NUVA vs SILK Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas SILK's P/E ratio is -18.96. In terms of profitability, NUVA's ROE is +0.05%, compared to SILK's ROE of -0.35%. Regarding short-term risk, NUVA is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check SILK's competition here
IRadimed Corporation (NASDAQ: IRMD)
NUVA vs IRMD Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while IRMD trades at $87.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas IRMD's P/E ratio is 43.80. In terms of profitability, NUVA's ROE is +0.05%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, NUVA is more volatile compared to IRMD. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check IRMD's competition here
Paragon 28, Inc. (NYSE: FNA)
NUVA vs FNA Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas FNA's P/E ratio is -19.83. In terms of profitability, NUVA's ROE is +0.05%, compared to FNA's ROE of -0.35%. Regarding short-term risk, NUVA is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check FNA's competition here
Bioventus Inc. (NASDAQ: BVS)
NUVA vs BVS Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, BVS has a market cap of 941M. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while BVS trades at $13.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas BVS's P/E ratio is 18.28. In terms of profitability, NUVA's ROE is +0.05%, compared to BVS's ROE of +0.28%. Regarding short-term risk, NUVA is more volatile compared to BVS. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check BVS's competition here
CeriBell, Inc. (NASDAQ: CBLL)
NUVA vs CBLL Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, CBLL has a market cap of 882.2M. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while CBLL trades at $23.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas CBLL's P/E ratio is -14.26. In terms of profitability, NUVA's ROE is +0.05%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, NUVA is more volatile compared to CBLL. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check CBLL's competition here
InMode Ltd. (NASDAQ: INMD)
NUVA vs INMD Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, INMD has a market cap of 873.7M. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while INMD trades at $15.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas INMD's P/E ratio is 10.56. In terms of profitability, NUVA's ROE is +0.05%, compared to INMD's ROE of +0.12%. Regarding short-term risk, NUVA is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check INMD's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
NUVA vs AVR Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, AVR has a market cap of 868.3M. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while AVR trades at $8.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas AVR's P/E ratio is -4.00. In terms of profitability, NUVA's ROE is +0.05%, compared to AVR's ROE of -0.78%. Regarding short-term risk, NUVA is more volatile compared to AVR. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check AVR's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
NUVA vs CSII Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas CSII's P/E ratio is -20.83. In terms of profitability, NUVA's ROE is +0.05%, compared to CSII's ROE of -0.14%. Regarding short-term risk, NUVA is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check CSII's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
NUVA vs SIBN Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, SIBN has a market cap of 840.4M. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while SIBN trades at $18.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas SIBN's P/E ratio is -55.74. In terms of profitability, NUVA's ROE is +0.05%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, NUVA is more volatile compared to SIBN. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check SIBN's competition here
Beta Bionics, Inc. (NASDAQ: BBNX)
NUVA vs BBNX Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, BBNX has a market cap of 813.4M. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while BBNX trades at $18.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas BBNX's P/E ratio is -11.97. In terms of profitability, NUVA's ROE is +0.05%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, NUVA is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for NUVA.Check BBNX's competition here
Varex Imaging Corporation (NASDAQ: VREX)
NUVA vs VREX Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, VREX has a market cap of 778.9M. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while VREX trades at $18.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas VREX's P/E ratio is 19.47. In terms of profitability, NUVA's ROE is +0.05%, compared to VREX's ROE of +0.05%. Regarding short-term risk, NUVA is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check VREX's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
NUVA vs AHCO Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, AHCO has a market cap of 775.5M. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while AHCO trades at $5.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas AHCO's P/E ratio is 11.63. In terms of profitability, NUVA's ROE is +0.05%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, NUVA is less volatile compared to AHCO. This indicates lower risk in terms of short-term price fluctuations for NUVA.Check AHCO's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
NUVA vs SSII Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, SSII has a market cap of 766.5M. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while SSII trades at $3.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas SSII's P/E ratio is -74.70. In terms of profitability, NUVA's ROE is +0.05%, compared to SSII's ROE of -0.27%. Regarding short-term risk, NUVA is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for NUVA.Check SSII's competition here
BrainsWay Ltd. (NASDAQ: BWAY)
NUVA vs BWAY Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, BWAY has a market cap of 646M. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while BWAY trades at $16.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas BWAY's P/E ratio is 41.84. In terms of profitability, NUVA's ROE is +0.05%, compared to BWAY's ROE of +0.12%. Regarding short-term risk, NUVA is less volatile compared to BWAY. This indicates lower risk in terms of short-term price fluctuations for NUVA.Check BWAY's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
NUVA vs KIDS Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, KIDS has a market cap of 642.4M. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while KIDS trades at $25.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas KIDS's P/E ratio is -21.19. In terms of profitability, NUVA's ROE is +0.05%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, NUVA is more volatile compared to KIDS. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check KIDS's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
NUVA vs CTKB Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, CTKB has a market cap of 631.5M. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while CTKB trades at $4.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas CTKB's P/E ratio is -25.91. In terms of profitability, NUVA's ROE is +0.05%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, NUVA is more volatile compared to CTKB. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check CTKB's competition here
Surmodics, Inc. (NASDAQ: SRDX)
NUVA vs SRDX Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas SRDX's P/E ratio is -34.66. In terms of profitability, NUVA's ROE is +0.05%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, NUVA is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check SRDX's competition here
Delcath Systems, Inc. (NASDAQ: DCTH)
NUVA vs DCTH Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, DCTH has a market cap of 599.3M. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while DCTH trades at $17.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas DCTH's P/E ratio is 1736.00. In terms of profitability, NUVA's ROE is +0.05%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, NUVA is more volatile compared to DCTH. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check DCTH's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
NUVA vs APEN Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas APEN's P/E ratio is -9.43. In terms of profitability, NUVA's ROE is +0.05%, compared to APEN's ROE of -0.85%. Regarding short-term risk, NUVA is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check APEN's competition here
Cerus Corporation (NASDAQ: CERS)
NUVA vs CERS Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, CERS has a market cap of 572.3M. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while CERS trades at $2.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas CERS's P/E ratio is -56.69. In terms of profitability, NUVA's ROE is +0.05%, compared to CERS's ROE of -0.10%. Regarding short-term risk, NUVA is less volatile compared to CERS. This indicates lower risk in terms of short-term price fluctuations for NUVA.Check CERS's competition here
ZimVie Inc. (NASDAQ: ZIMV)
NUVA vs ZIMV Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, NUVA's ROE is +0.05%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, NUVA is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check ZIMV's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
NUVA vs TCMD Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, TCMD has a market cap of 534.8M. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while TCMD trades at $23.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas TCMD's P/E ratio is 26.94. In terms of profitability, NUVA's ROE is +0.05%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, NUVA is less volatile compared to TCMD. This indicates lower risk in terms of short-term price fluctuations for NUVA.Check TCMD's competition here
NeuroPace, Inc. (NASDAQ: NPCE)
NUVA vs NPCE Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, NPCE has a market cap of 494.7M. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while NPCE trades at $14.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas NPCE's P/E ratio is -22.32. In terms of profitability, NUVA's ROE is +0.05%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, NUVA is less volatile compared to NPCE. This indicates lower risk in terms of short-term price fluctuations for NUVA.Check NPCE's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
NUVA vs CLPT Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, CLPT has a market cap of 462.4M. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while CLPT trades at $15.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas CLPT's P/E ratio is -13.07. In terms of profitability, NUVA's ROE is +0.05%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, NUVA is more volatile compared to CLPT. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check CLPT's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
NUVA vs SGHT Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, SGHT has a market cap of 452.7M. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while SGHT trades at $8.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas SGHT's P/E ratio is -14.86. In terms of profitability, NUVA's ROE is +0.05%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, NUVA is less volatile compared to SGHT. This indicates lower risk in terms of short-term price fluctuations for NUVA.Check SGHT's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
NUVA vs OFIX Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, OFIX has a market cap of 411.5M. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while OFIX trades at $10.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas OFIX's P/E ratio is -13.30. In terms of profitability, NUVA's ROE is +0.05%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, NUVA is more volatile compared to OFIX. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check OFIX's competition here
Carlsmed, Inc. (NASDAQ: CARL)
NUVA vs CARL Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, CARL has a market cap of 380.3M. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while CARL trades at $13.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas CARL's P/E ratio is -9.78. In terms of profitability, NUVA's ROE is +0.05%, compared to CARL's ROE of -0.38%. Regarding short-term risk, NUVA is more volatile compared to CARL. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check CARL's competition here
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
NUVA vs PACB Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, PACB has a market cap of 357.2M. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while PACB trades at $1.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas PACB's P/E ratio is -2.80. In terms of profitability, NUVA's ROE is +0.05%, compared to PACB's ROE of -49.62%. Regarding short-term risk, NUVA is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for NUVA.Check PACB's competition here
Picard Medical, Inc. (AMEX: PMI)
NUVA vs PMI Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, PMI has a market cap of 354.8M. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while PMI trades at $3.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas PMI's P/E ratio is -2.88. In terms of profitability, NUVA's ROE is +0.05%, compared to PMI's ROE of +4.99%. Regarding short-term risk, NUVA is less volatile compared to PMI. This indicates lower risk in terms of short-term price fluctuations for NUVA.Check PMI's competition here
Perspective Therapeutics, Inc. (AMEX: CATX)
NUVA vs CATX Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, CATX has a market cap of 352.4M. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while CATX trades at $3.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas CATX's P/E ratio is -2.19. In terms of profitability, NUVA's ROE is +0.05%, compared to CATX's ROE of -0.42%. Regarding short-term risk, NUVA is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for NUVA.Check CATX's competition here
Electromed, Inc. (AMEX: ELMD)
NUVA vs ELMD Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, ELMD has a market cap of 351.1M. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while ELMD trades at $42.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas ELMD's P/E ratio is 36.24. In terms of profitability, NUVA's ROE is +0.05%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, NUVA is more volatile compared to ELMD. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check ELMD's competition here
TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
NUVA vs TLSI Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, TLSI has a market cap of 346.7M. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while TLSI trades at $5.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas TLSI's P/E ratio is -3.35. In terms of profitability, NUVA's ROE is +0.05%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, NUVA is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for NUVA.Check TLSI's competition here
CapsoVision, Inc. (NASDAQ: CV)
NUVA vs CV Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, CV has a market cap of 339.3M. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while CV trades at $6.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas CV's P/E ratio is -2.72. In terms of profitability, NUVA's ROE is +0.05%, compared to CV's ROE of +1.27%. Regarding short-term risk, NUVA is less volatile compared to CV. This indicates lower risk in terms of short-term price fluctuations for NUVA.Check CV's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
NUVA vs SENS Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, SENS has a market cap of 323.1M. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while SENS trades at $7.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas SENS's P/E ratio is -3.86. In terms of profitability, NUVA's ROE is +0.05%, compared to SENS's ROE of -1.66%. Regarding short-term risk, NUVA is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for NUVA.Check SENS's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
NUVA vs SMLR Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas SMLR's P/E ratio is 3.92. In terms of profitability, NUVA's ROE is +0.05%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, NUVA is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check SMLR's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
NUVA vs TMCI Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, TMCI has a market cap of 292.6M. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while TMCI trades at $4.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas TMCI's P/E ratio is -4.80. In terms of profitability, NUVA's ROE is +0.05%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, NUVA is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for NUVA.Check TMCI's competition here
RxSight, Inc. (NASDAQ: RXST)
NUVA vs RXST Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, RXST has a market cap of 290.2M. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while RXST trades at $7.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas RXST's P/E ratio is -7.54. In terms of profitability, NUVA's ROE is +0.05%, compared to RXST's ROE of -0.17%. Regarding short-term risk, NUVA is less volatile compared to RXST. This indicates lower risk in terms of short-term price fluctuations for NUVA.Check RXST's competition here
Anika Therapeutics, Inc. (NASDAQ: ANIK)
NUVA vs ANIK Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, ANIK has a market cap of 283.3M. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while ANIK trades at $21.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas ANIK's P/E ratio is 43.20. In terms of profitability, NUVA's ROE is +0.05%, compared to ANIK's ROE of -0.03%. Regarding short-term risk, NUVA is less volatile compared to ANIK. This indicates lower risk in terms of short-term price fluctuations for NUVA.Check ANIK's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
NUVA vs MGRM Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas MGRM's P/E ratio is -12.00. In terms of profitability, NUVA's ROE is +0.05%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, NUVA is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check MGRM's competition here
Profound Medical Corp. (NASDAQ: PROF)
NUVA vs PROF Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, PROF has a market cap of 242.4M. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while PROF trades at $6.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas PROF's P/E ratio is -5.38. In terms of profitability, NUVA's ROE is +0.05%, compared to PROF's ROE of -0.56%. Regarding short-term risk, NUVA is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for NUVA.Check PROF's competition here
Nevro Corp. (NYSE: NVRO)
NUVA vs NVRO Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas NVRO's P/E ratio is -1.91. In terms of profitability, NUVA's ROE is +0.05%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, NUVA is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check NVRO's competition here
Neuronetics, Inc. (NASDAQ: STIM)
NUVA vs STIM Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, STIM has a market cap of 210.9M. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while STIM trades at $3.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas STIM's P/E ratio is -5.61. In terms of profitability, NUVA's ROE is +0.05%, compared to STIM's ROE of -1.51%. Regarding short-term risk, NUVA is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for NUVA.Check STIM's competition here
Avita Medical Inc. (NASDAQ: RCEL)
NUVA vs RCEL Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, RCEL has a market cap of 199M. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while RCEL trades at $8.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas RCEL's P/E ratio is -5.10. In terms of profitability, NUVA's ROE is +0.05%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, NUVA is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for NUVA.Check RCEL's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
NUVA vs BSGM Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas BSGM's P/E ratio is -5.81. In terms of profitability, NUVA's ROE is +0.05%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, NUVA is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for NUVA.Check BSGM's competition here
Lucid Diagnostics Inc. (NASDAQ: LUCD)
NUVA vs LUCD Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, LUCD has a market cap of 184.1M. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while LUCD trades at $0.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas LUCD's P/E ratio is -2.61. In terms of profitability, NUVA's ROE is +0.05%, compared to LUCD's ROE of -0.02%. Regarding short-term risk, NUVA is less volatile compared to LUCD. This indicates lower risk in terms of short-term price fluctuations for NUVA.Check LUCD's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
NUVA vs MDGS Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas MDGS's P/E ratio is -0.27. In terms of profitability, NUVA's ROE is +0.05%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, NUVA is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for NUVA.Check MDGS's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
NUVA vs FOCL Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, FOCL has a market cap of 178M. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while FOCL trades at $4.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas FOCL's P/E ratio is -5.80. In terms of profitability, NUVA's ROE is +0.05%, compared to FOCL's ROE of -1.38%. Regarding short-term risk, NUVA is less volatile compared to FOCL. This indicates lower risk in terms of short-term price fluctuations for NUVA.Check FOCL's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
NUVA vs QIPT Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas QIPT's P/E ratio is -15.87. In terms of profitability, NUVA's ROE is +0.05%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, NUVA is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check QIPT's competition here
Inogen, Inc. (NASDAQ: INGN)
NUVA vs INGN Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, INGN has a market cap of 157.3M. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while INGN trades at $5.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas INGN's P/E ratio is -6.38. In terms of profitability, NUVA's ROE is +0.05%, compared to INGN's ROE of -0.13%. Regarding short-term risk, NUVA is more volatile compared to INGN. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check INGN's competition here
Quanterix Corporation (NASDAQ: QTRX)
NUVA vs QTRX Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, QTRX has a market cap of 134.7M. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while QTRX trades at $2.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas QTRX's P/E ratio is -1.79. In terms of profitability, NUVA's ROE is +0.05%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, NUVA is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for NUVA.Check QTRX's competition here
Owlet, Inc. (NYSE: OWLT)
NUVA vs OWLT Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, OWLT has a market cap of 114.5M. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while OWLT trades at $6.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas OWLT's P/E ratio is -45.21. In terms of profitability, NUVA's ROE is +0.05%, compared to OWLT's ROE of -0.50%. Regarding short-term risk, NUVA is less volatile compared to OWLT. This indicates lower risk in terms of short-term price fluctuations for NUVA.Check OWLT's competition here
iCAD, Inc. (NASDAQ: ICAD)
NUVA vs ICAD Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas ICAD's P/E ratio is -20.37. In terms of profitability, NUVA's ROE is +0.05%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, NUVA is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for NUVA.Check ICAD's competition here
Solana Company (NASDAQ: HSDT)
NUVA vs HSDT Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, HSDT has a market cap of 105.1M. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while HSDT trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas HSDT's P/E ratio is -0.02. In terms of profitability, NUVA's ROE is +0.05%, compared to HSDT's ROE of -1.55%. Regarding short-term risk, NUVA is less volatile compared to HSDT. This indicates lower risk in terms of short-term price fluctuations for NUVA.Check HSDT's competition here
Hancock Jaffe Laboratories (NASDAQ: HJLI)
NUVA vs HJLI Comparison August 2026
NuVasive, Inc. (NASDAQ: NUVA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NUVA stands at 2.1B. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, NUVA is priced at $39.75 on the NASDAQ, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NUVA currently has a P/E ratio of 75.00, whereas HJLI's P/E ratio is N/A. In terms of profitability, NUVA's ROE is +0.05%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, NUVA is less volatile compared to HJLI. This indicates lower risk in terms of short-term price fluctuations for NUVA.Check HJLI's competition here